ICORG launch of the Group’s first iPhone App, is planned for an early October launch. It is currently in beta testing. This will be the Group’s own members-only App where those who download it will be able to search all available research options for any specific patient group. There will be many other functions it […]
Post-Graduate Opportunities in Translational Cancer Research
Date: Friday December 17th 2010
Time: 11:00 – 17:00
Venue: Trinity College Dublin
ICORG would like to highlight an abstract relating to an ICORG in-house study, The PAD (Ireland) Study for Patients with Refractory and Relapsed Myeloma (ICORG 05-01) which was presented at the 12th International Myeloma Workshop, which took place in Washington, USA, from 26th February to 1st March 2009.
Myriam is a scientist with an oncology clinical trials background who has worked as a coordinator at the Institute Claudius Regaud, Toulouse, France. This is a highly regarded cancer centre which is a big centre in an ICORG like network in France.
New ICORG Vice-Chair Dr Ray McDermott, Consultant Medical Oncologist, AMNCH; ICORG/ECOG PI, has recently been elected unopposed as the new Vice Chair of ICORG. He began his four year term of office on 1st January 2009.
ICORG’s new Chair Dr Paul Browne, Consultant Haematologist, St James’s Hospital, took up his four year term of office on 1st January 2009.
We would like to welcome ICORG’s new Chair, Dr Paul Browne, Consultant Haematologist, St James’s Hospital, who takes up his four year term of office on 1st January 2009.
The ICORG Pharmacovigilance Unit has recently expanded and is pleased to welcome Armelle Donohoe, PhV Consultant and Sandra Boldrin, PhV Associate.
Armelle has over ten years experience in pharmacovigilance, and Sandra has worked in the area for two years.
Sandra is now the third ICORG employee to successfully complete the EMEA’s EudraVigilance training programme.
For more information on the ICORG group structure click here
Update on availability of the experimental drug abiraterone for treatment of prostate cancer in Ireland
On July 22nd 2008, exciting positive Phase 1 results were published for a new drug abiraterone acetate (Cougar Biotechnology Inc.®)in prostate cancer patients with advanced disease.
We would like to remind you that ESMO offers grants to enhance implementation and research of Palliative Care in oncology, as adequate Palliative Care is one of the cornerstones of oncology practice.
If you are interested or your have started a research on Palliative Care, please download the application form, complete and send it along with the requested documentation by 1 June 2008.